前のページに戻る
この文献は全文を取り寄せることができます
JDreamⅢ複写サービスから文献全文の複写（冊子体のコピー）をお申込みできます。
ご利用には、G-Searchデータベースサービスまたは、JDreamⅢのIDが必要です。
ご利用には、G-Searchデータベースサービスまたは、JDreamⅢのIDが必要です。
既に、G-Searchデータベースサービスまたは、JDreamⅢのIDをお持ちの方
JDreamⅢ複写サービスのご利用が初めての方
取り寄せる文献のタイトルと詳細
文献
J-GLOBAL ID：202202241765189743
整理番号：22A1160312
神経因性疼痛の潜在的な治療のための高選択性,CNS浸透性,および経口活性アダプター蛋白質2関連キナーゼ1(AAK1)阻害剤の新規クラスとしてのビアリールアルキルエーテルの発見と最適化【JST・京大機械翻訳】
Discovery and Optimization of Biaryl Alkyl Ethers as a Novel Class of Highly Selective, CNS-Penetrable, and Orally Active Adaptor Protein-2-Associated Kinase 1 (AAK1) Inhibitors for the Potential Treatment of Neuropathic Pain
Luo Guanglin
(Department of Neuroscience Chemistry, Bristol-Myers Squibb Company, Connecticut, United States)
,
Chen Ling
(Department of Neuroscience Chemistry, Bristol-Myers Squibb Company, Connecticut, United States)
,
Kostich Walter A.
(Department of Neuroscience Discovery Biology, Bristol-Myers Squibb Company, Connecticut, United States)
,
Hamman Brian
(Lexicon Pharmaceuticals, Texas, United States)
,
Allen Jason
(Lexicon Pharmaceuticals, Texas, United States)
,
Easton Amy
(Department of Neuroscience Discovery Biology, Bristol-Myers Squibb Company, Connecticut, United States)
,
Bourin Clotilde
(Department of Neuroscience Discovery Biology, Bristol-Myers Squibb Company, Connecticut, United States)
,
Gulianello Michael
(Department of Neuroscience Discovery Biology, Bristol-Myers Squibb Company, Connecticut, United States)
,
Lippy Jonathan
(Department of Lead Evaluation, Bristol Myers Squibb Company, New Jersey, United States)
,
Nara Susheel
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Pattipati Sreenivasulu Naidu
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Dandapani Kumaran
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Dokania Manoj
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Vattikundala Pradeep
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Sharma Vivek
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Elavazhagan Saravanan
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Verma Manoj Kumar
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Lal Das Manish
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Wagh Santosh
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Balakrishnan Anand
(Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Company, Connecticut, United States)
,
Johnson Benjamin M.
(Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Company, Connecticut, United States)
,
Santone Kenneth S.
(Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Company, Connecticut, United States)
,
Thalody George
(Discovery Toxicology, Bristol Myers Squibb Company, New Jersey, United States)
,
Denton Rex
(Discovery Toxicology, Bristol Myers Squibb Company, New Jersey, United States)
,
Saminathan Hariharan
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Holenarsipur Vinay K.
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Kumar Anoop
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Rao Abhijith
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Putlur Siva Prasad
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Sarvasiddhi Sarat Kumar
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Shankar Ganesh
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Louis Justin V.
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Ramarao Manjunath
(Biocon-Bristol Myers Squibb Research and Development Centre, India)
,
Conway Charles M.
(Department of Neuroscience Discovery Biology, Bristol-Myers Squibb Company, Connecticut, United States)
,
Li Yu-Wen
(Department of Neuroscience Discovery Biology, Bristol-Myers Squibb Company, Connecticut, United States)
,
Pieschl Rick
(Department of Neuroscience Discovery Biology, Bristol-Myers Squibb Company, Connecticut, United States)
,
Tian Yuan
(Department of Neuroscience Discovery Biology, Bristol-Myers Squibb Company, Connecticut, United States)
,
Hong Yang
(Department of Neuroscience Discovery Biology, Bristol-Myers Squibb Company, Connecticut, United States)
,
Bristow Linda
(Department of Neuroscience Discovery Biology, Bristol-Myers Squibb Company, Connecticut, United States)
,
Albright Charles F.
(Department of Neuroscience Discovery Biology, Bristol-Myers Squibb Company, Connecticut, United States)
,
Bronson Joanne J.
(Department of Neuroscience Chemistry, Bristol-Myers Squibb Company, Connecticut, United States)
,
Macor John E.
(Department of Neuroscience Chemistry, Bristol-Myers Squibb Company, Connecticut, United States)
,
Dzierba Carolyn D.
(Department of Neuroscience Chemistry, Bristol-Myers Squibb Company, Connecticut, United States)
資料名：
Journal of Medicinal Chemistry
(Journal of Medicinal Chemistry)
巻： 65 号： 6 ページ： 4534-4564 発行年： 2022年
JST資料番号： D0102A ISSN： 0022-2623 CODEN： JMCMAR 資料種別： 逐次刊行物 (A)
記事区分： 原著論文 発行国： アメリカ合衆国 (USA) 言語： 英語 (EN)
JDreamⅢ複写サービスとは
JDreamⅢ複写サービスは、学術文献の全文を複写（コピー）して取り寄せできる有料サービスです。インターネットに公開されていない文献や、図書館に収録されていない文献の全文を、オンラインで取り寄せることができます。J-GLOBALの整理番号にも対応しているので、申し込みも簡単にできます。全文の複写（コピー）は郵送またはFAXでお送りします
※ご利用には、G-Searchデータベースサービスまたは、JDreamⅢのIDが必要です
※初めてご利用される方は、JDreamⅢ複写サービスのご案内をご覧ください。
※ご利用には、G-Searchデータベースサービスまたは、JDreamⅢのIDが必要です
※初めてご利用される方は、JDreamⅢ複写サービスのご案内をご覧ください。